Dipeptiven

Per 100 mL N(2)-L-alanyl-L-glutamine 20 g (equiv to L-alanine 8.2 g, L-glutamine 13.46 g)

Part of a clinical nutrition regimen in patients in hypercatabolic &/or hypermetabolic states together w/ parenteral or enteral nutrition or combination of both.

The max daily dose of N(2)–L-alanyl-L-glutamine 0.5 g/kg should be administered in combination w/ at least 1 g amino acids/protein/kg/day. Max duration: 3 wk.

Severe renal insufficiency (CrCl <25 mL/min), severe hepatic insufficiency, severe metabolic acidosis or known hypersensitivity to N(2)-L-alanyl-L-glutamine or to any of the excipients.

Monitor regularly liver function parameters in patient w/ compensated hepatic insufficiency. Control serum electrolytes, serum osmolarity, water balance, acid-base status & liver function tests (alkaline phosphatase, ALT, AST) & possible symptoms of hyperammonaemia. Monitor enzymes alkaline phosphatase, GPT, GOT, bilirubin level & the acid-base status. The choice of a peripheral or central vein depends on the final osmolarity of the mixture. The general accepted limit for peripheral infusion is about 800 mosmol/L but varies considerably w/ age & general condition of the patient & the characteristics of the peripheral veins. Experience w/ the use of Dipeptiven for longer periods than 9 days is limited. Pregnancy & lactation. Childn.

Parenteral Nutritional Products

B05XB02 - alanyl glutamine ; Belongs to the class of amino acids solutions used in I.V. solutions.

P₁S₁S₃